Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
-
Randomized Controlled Trial Multicenter Study Comparative Study
Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial.
To examine the tolerability and adverse events reported in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). ⋯ Acetazolamide appears to have an acceptable safety profile at dosages up to 4 g/d in the treatment of idiopathic intracranial hypertension. The majority of participants in the Idiopathic Intracranial Hypertension Treatment Trial were able to tolerate acetazolamide above 1 g/d for 6 months.